MSMartin Kryspin Sørensen

Martin Kryspin Sørensen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Martin Kryspin Sørensen has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Factors Associated With Prolonged Hospital Stay After Craniotomy for Tumor

    by Martin Kryspin Sørensen, Alexandra Vassilieva, Mira Rn Søgaard Jørgensen, Jane Skjøth-Rasmussen, Pernille Vinding Rn Hansen, Nana Askjær-Friis, Lisette Willumsen, Dorte Aldershvile, Tenna Bach Rn Damhøj, Louise Corneliussen Crna Rughave, et al.

  • Open Access

    Novel Urokinase-Type Plasminogen Activator Receptor-Targeting Optical Imaging Agent ICG-Glu-Glu-AE105 for Visualization of Malignant Glioma During Surgery: First-in-Human Study in 35 Patients with Brain Cancer

    by Jane Skjøth-Rasmussen, Aleena Azam, Karina Juhl, Sara Ginsborg, Martin Kryspin Sørensen, Christine Sølling, Carl Christian Larsen, Bjarne Winther Kristensen, David Scheie, Andreas Kjaer

    BACKGROUND AND OBJECTIVES: Glioblastoma is an aggressive form of brain cancer for which surgery is the keystone in treatment before oncological treatment. Improving surgical resection without jeopardizing the outcome is eminent, and a fluorescent drug to aid surgical outcome is warranted. To evaluate the safety and the efficacy of a novel urokinase-type Plasminogen Activator Receptor-targeting near-infrared optical imaging agent, ICG-Glu-Glu-AE105 (FG001), in patients with malignant glioma (glioblastoma). METHODS: First-in-human phase I dose escalation and time elaboration study in 35 patients undergoing surgery for glioblastoma. The tumor-to-background ratio (TBR) was measured on near-infrared images as an objective measure of image contrast. Biopsies were taken during surgery from areas with and without fluorescence (FG001) and compared with pathology as reference. Efficacy was evaluated as sensitivity and specificity of FG001 to detect tumor tissue. The study was conducted with close safety monitoring. RESULTS: Administration of FG001 at a dose of 36 mg, 12 to 17 hours before surgery, resulted in optimal image contrast between tumor and normal brain tissue, with a mean TBR of 3.6. A high sensitivity (79%) and specificity (100%) for the detection of tumor tissue was found. Safety monitoring during the study identified only a few related adverse events, all of which were of mild grade. CONCLUSION: FG001 was found to be safe and well tolerated in the patients included in the study. The optimal dose of FG001 was selected on the basis of videos taken during the surgery and the measured TBR values. A dose of 36 mg administered 16 hours (mean) before the surgery showed the best contrast (TBR values) and optimal visualization of the tumor delineation. Histology demonstrated good sensitivity of FG001.


  • Subarachnoid haemorrhage in a patient with undiagnosed aortic coarctation

    by Anders Peder Højer Karlsen, Michael Rahbek Schmidt, Trine Stavnsgaard, Martin Kryspin Sørensen

    A man in his mid-30s was admitted with a thunderclap headache. He was conscious and hypertensive. A decade earlier, severe hypertension had been diagnosed and extensively investigated without revealing an underlying cause. Brain imaging showed subarachnoid haemorrhage caused by a ruptured pericallosal aneurysm. Endovascular occlusion was attempted, but as the sheath could not pass the aortic arch, it was converted to surgical aneurismal clipping. Intraoperative blood pressure measurement revealed a peak-to-peak gradient of 100 mm Hg across the aortic arch and an ankle/brachial index of 0.46 (normal range 0.9–1.2). Aortic coarctation was suspected, and angiographic imaging and echocardiography confirmed the diagnosis. Subacute direct stenting was performed, which normalised the peak-to-peak gradient and ankle/brachial index. To minimise the risk of severe complications, early diagnosis of aortic coarctation is important and can be facilitated by ankle/brachial index and echocardiography in the suprasternal view.


  • Letter: Enhanced Recovery After Neurosurgery for Brain Tumors – A Critical Reappraisal

    by Martin Kryspin Sørensen, Henrik Kehlet, Christine Sølling, Kirsten Møller


  • Normative Values and Interrelationship of MDVP Voice Analysis Parameters Before and After Endotracheal Intubation

    by Martin Kryspin Sørensen, Tina Trier Durck, Kristian Hveysel Bork, Niels Rasmussen


  • Laryngeal morbidity after tracheal intubation: the Endoflex® tube compared to conventional endotracheal intubation with stylet

    by M. K. Sørensen, N. Rasmussen, M. S. Kristensen, M. Bøttger, B. B. Fredensborg, C. M. Hansen, L. S. Rasmussen

    Background: Tracheal intubation may cause vocal fold damage. The trial was designed to assess laryngeal morbidity comparing the Endoflex® tube with a conventional endotracheal tube with stylet. We hypothesised that laryngeal morbidity within the first 24 h after extubation would be lower with the Endoflex tube than with the conventional endotracheal tube with stylet because of less rigidity.Methods: This randomised trial included 130 elective surgical patients scheduled for general anaesthesia with endotracheal intubation. Pre‐ and post‐operative assessment of hoarseness, vocal fold pathology, and voice analysis using the Multidimensional Voice Program was performed. Induction of anaesthesia was standardised. After complete neuromuscular paralysis, intubation was done with an Endoflex tube or a conventional endotracheal tube with stylet.Results: Post‐operative hoarseness was found in 45% with the Endoflex tube and 55% with the endotracheal tube with stylet at 24 h after extubation (P = 0.44). Post‐operative vocal fold injury was present in 23% in the Endoflex tube group and in 36% in the endotracheal tube with stylet group (P = 0.13). The increase in shimmer, the voice analysis variable reflecting vocal fold oedema, was 0.5% in the Endoflex tube group and 2.5% in the endotracheal tube with stylet group (P = 0.02).Conclusion: No significant difference was found in the incidence of hoarseness or vocal fold injury using the Endoflex tube. However, the statistically significant lower increase in the shimmer values in that group implies that the Endoflex may be associated with less laryngeal morbidity.


  • Open Access

    Reply from the authors

    by M. K. SØRensen, C. Bretlau, M. R. GÄTke, A. M. SØRensen, L. S. Rasmussen

    Editor—We appreciate Dr McCahon's comments and his interest in our study.1 We definitely did not study a ‘can't intubate, can't ventilate’ (CICV) situation where oxygenation through the cricothyroid membrane may be the way to proceed when desaturation has occurred.

  • Open Access

    Endotracheal intubation with airtraq® versus storz® videolaryngoscope in children younger than two years - a randomized pilot-study

    by Martin Kryspin Sørensen, Rolf Holm-Knudsen

    Background: New laryngoscopes have become available for use in small children. The aim of the study was to compare the Storz® videolaryngoscope (SVL) to the Airtraq® Optical laryngoscope (AOL) for tracheal intubation in children younger than two years of age who had a normal airway assessment. Our hypothesis was that the SVL would have a better success rate than the AOL. Methods: Ten children aged 2 years or younger scheduled for elective cleft lip/palate surgery were included. The anesthesia was standardized and a Cormack-Lehane (CL)-score was obtained using a Macintosh laryngoscope. After randomization CL-score and endotracheal tube positioning in front of the glottis was performed with one device, followed by the same procedure and intubation with the other device. The video-feed was recorded along with real-time audio. The primary endpoint was the success rate, defined as intubation in first attempt. Secondary endpoints were the time from start of laryngoscopy to CL-score, tube positioning in front of the glottis, and intubation. Results: Two intubation attempts were needed in two of five patients randomized to the SVL. The difference in time (SVL vs. AOL) to CL-score was 4.5 sec (p = 0.0449). The difference in time (SVL vs. AOL) to tube positioning was 11.6 sec (p = 0.0015). Time to intubation was 29.0 sec for SVL and 15.8 sec for AOL. Conclusion: No difference in the success rate of endotracheal intubation could be established in this ten patient sample of children younger than two years with a normal airway assessment scheduled for elective cleft lip/palate surgery. However, the Airtraq® Optical videolaryngoscope showed a number of time related advantages over the Storz® videolaryngoscope. Because of the small sample size a larger trial is needed to confirm these findings. Both devices were considered safe in all intubations. Trial registration: ClinicalTrials.gov; Identifier NCT01090726.


  • Open Access

    Rapid sequence induction and intubation with rocuronium–sugammadex compared with succinylcholine: a randomized trial

    by M. K. Sørensen, C. Bretlau, M. R. Gätke, A. M. Sørensen, L. S. Rasmussen

    An unanticipated difficult airway may arise during rapid sequence induction and intubation (RSII). The aim of the trial was to assess how rapidly spontaneous ventilation could be re-established after RSII. We hypothesized that the time period from tracheal intubation to spontaneous ventilation would be shorter with rocuronium–sugammadex than with succinylcholine. This randomized and patient- and observer-blinded trial was approved by the regional Ethics Committee and the Danish Medicines Agency. We included elective surgical patients undergoing general anaesthesia for RSII using alfentanil (10 µg kg−1), propofol (2 mg kg−1), and either succinylcholine (1 mg kg−1) or rocuronium (1 mg kg−1). Sugammadex (16 mg kg−1) was given in the rocuronium group after tracheal intubation. The primary endpoint was the time from correct placement of the tracheal tube to spontaneous ventilation, defined as a respiratory rate of more than 8 bpm and a tidal volume of at least 3 ml kg−1 for 30 s. We included 61 patients; of whom, 55 were evaluated for the primary endpoint. The median time from tracheal intubation to spontaneous ventilation was 406 s with succinylcholine and 216 s with rocuronium–sugammadex (P = 0.002). The median time from tracheal intubation to 90% recovery of the first twitch in train-of-four (T1 90%) was 518 s with succinylcholine and 168 s with rocuronium–sugammadex (P < 0.0001). Intubation conditions and time to tracheal intubation were not significantly different. RSII with rocuronium followed by reversal with sugammadex allowed earlier re-establishment of spontaneous ventilation than with succinylcholine.